Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invitrogen Entering Gene Analysis Market Via Research Genetics

This article was originally published in The Gray Sheet

Executive Summary

Invitrogen's acquisition of Research Genetics in a stock transaction valued at $158 mil. will allow the company's expanded sales force to offer products and services in four key areas of the genomic discovery cycle.

You may also be interested in...



Invitrogen

Research partnership with the Novartis Institute for Functional Genomics is announced Dec. 17. The agreement allows Novartis access to Invitrogen's cloning and expression kits in exchange for commercial rights to any genes discovered by NIFG using the technology (1see related story, p. 19)

Invitrogen

Research partnership with the Novartis Institute for Functional Genomics is announced Dec. 17. The agreement allows Novartis access to Invitrogen's cloning and expression kits in exchange for commercial rights to any genes discovered by NIFG using the technology (1see related story, p. 19)

Invitrogen/Novex

Definitive stock-swap merger agreement valued at over $50 mil. would combine San Diego-based Novex, a supplier of pre-cast electrophoresis gels and related instruments, with Invitrogen, maker of research tool kits for gene cloning and protein expression, also based in San Diego. Combined annual revenues would exceed $50 mil. Invitrogen revenues were $31.4 mil. in 1998; net income was $3 mil. Novex generated revenues of $23.1 mil. for the fiscal year ended March 31, and net income of $1.1 mil. Acquisition of Novex is part of Invitrogen's strategy "to expand our leadership in providing products that accelerate gene discovery and analysis," the firm says

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel